Steris plc stock (IE00BFY8C754): valuation metrics back in focus after latest price move

Steris plc shares on the NYSE were last quoted around USD 215 on 05/29/2026, bringing valuation ratios such as P/E, EV/EBITDA and dividend yield back into focus for investors looking at the US-based sterilization and infection-prevention specialist.

Steris plc shares on the New York Stock Exchange, traded under the ticker STE, changed hands at about USD 215 in intraday dealings on 05/29/2026, following a trading range between roughly USD 209 and USD 217 over the prior sessions, according to data from Robinhood as of 05/29/2026. This places the Ireland-registered but US-listed healthcare equipment group squarely in the spotlight for investors in the United States who are reassessing valuation metrics after the latest move in the stock.

The stock price of around USD 215 on 05/29/2026 implies a market capitalization in the area of USD 21 billion and a trailing price-to-earnings ratio of about 26.8, based on Robinhood figures published on 05/29/2026. With a reported dividend yield near 1.2 percent on the same date, Steris offers a moderate income component in addition to potential capital appreciation, which may appeal to US investors comparing it with other healthcare names in the S&P 500 universe.

On the home market in the United States, Steris is primarily followed as a NYSE-listed healthcare equipment and services stock, and trading in US dollars remains the central reference point for global investors. In parallel, the shares can also be accessed by German investors via secondary trading venues such as Tradegate, where the stock is quoted in euros alongside the primary US listing, although liquidity and pricing are generally anchored by New York.

Beyond the day-to-day price action, institutional investors have continued to adjust their exposure to the company. On 05/29/2026, MarketBeat reported that Intech Investment Management LLC disclosed the purchase of 25,735 Steris shares in a recent filing, underscoring ongoing professional investor interest in the name. Such portfolio moves are often viewed as a data point on how asset managers position themselves within the broader US healthcare equipment sector.

Management guidance also frames the valuation debate. According to MarketBeat citing company guidance, Steris has set its fiscal year 2027 earnings-per-share outlook in a range of USD 11.10 to USD 11.30, and analysts currently anticipate EPS of roughly USD 11.18 for the ongoing fiscal year as of 05/29/2026. At a share price near USD 215, this implies a forward P/E ratio in the low 20s on that earnings base, giving investors a benchmark for comparing Steris to other US-listed medical equipment providers.

The stock’s valuation thus reflects both its earnings profile and investors’ perception of Steris’s role in infection prevention and sterilization markets that are closely tied to hospital procedure volumes and regulatory requirements. For US-based shareholders, the combination of earnings guidance and the share’s positioning within the NYSE healthcare cohort remains a key reference point when assessing whether the current price level aligns with their risk-return expectations.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Steris plc
• Sector/industry: Healthcare equipment and services, sterilization and infection prevention
• Headquarters/country: Dublin, Ireland / primary listing United States
• Core markets: North America, Europe and selected international healthcare markets
• Key revenue drivers: Sterilization systems, infection-prevention services and related healthcare consumables
• Home exchange/listing venue: New York Stock Exchange (STE)
• Trading currency: USD

Steris plc: core business model

Steris focuses on providing hospitals and healthcare providers with sterilization equipment, infection-prevention services and associated consumables that generate recurring revenue linked to procedure volumes and regulatory compliance.

Valuation metrics and multiples for Steris plc

Valuation has been a central theme for Steris on 05/29/2026, as the share price and updated guidance feed into commonly watched ratios. Based on Robinhood price data showing Steris at USD 215.40 with a trailing P/E of about 26.84 and a dividend yield near 1.2 percent as of 05/29/2026, investors can gauge how the stock is priced relative to earnings and income generation within the US healthcare equipment space. Taking the FY 2027 EPS guidance range of USD 11.10 to USD 11.30 from company commentary cited by MarketBeat on 05/29/2026, the implied forward earnings multiple falls to around the low 20s at current levels, which may be used as a reference point when comparing Steris with peers offering similar growth and margin profiles.

Enterprise-value-based ratios and cash-return metrics also contribute to the picture, even though detailed EV/EBITDA figures were not highlighted in the latest sources. The existing dividend yield of roughly 1.2 percent, combined with a healthcare-focused business backed by long-term contracts and recurring service revenues, suggests that Steris is positioned more as a quality compounder than as a high-yield income stock in US portfolios. For valuation-focused readers, the interplay of growth expectations, earnings guidance and the current trading range on the NYSE will remain key variables in judging how Steris fits in diversified equity strategies that track or benchmark against major US indices.

Conclusion

The latest trading around USD 215 on the NYSE and the associated P/E ratio near the high-20s have brought Steris’s valuation parameters back into the foreground for US investors weighing earnings expectations against price. With management’s fiscal 2027 EPS guidance and a dividend yield of roughly 1.2 percent framing forward-looking multiples, the stock sits at an intersection of growth and quality within the healthcare equipment space. How investors judge this balance relative to peers and broader market conditions will play a key role in determining whether Steris’s current valuation range can be sustained over the medium term.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.